ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCAâs lead development program is intended to be a direct implementation of those ideas. Gencaro⢠(bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF). ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaroâ˘, giving Gencaro⢠the potential to be the first genetically-targeted prevention treatment for AF. AF is considered to be an epidemic cardiovascular disease and AF therapies that are safe and effective for patients with heart failure is considered a major unmet medical need. The approved therapies for the treatment or prevention AF have certain disadvantages in heart failure patients, such as toxic or cardiovascular adverse effects, and most of the approved drugs for AF are contraindicated or have warnings in their prescribing information for such patients. We believe there is an unmet medical need for new AF treatments that have fewer side effects than currently available therapies and are more effective, particularly in heart failure patients. Source
No articles found.
Celldex is developing targeted therapeutics to address devastating diseases for wh...
Celldex is developing targeted therapeutics to ...
Spok, Inc., a wholly owned subsidiary of Spok Holdings, Inc. (NASDAQ: SPOK), headq...
Spok, Inc., a wholly owned subsidiary of Spok H...
AnaptysBio is a clinical-stage antibody development company advancing therapeutic ...
AnaptysBio is a clinical-stage antibody develop...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a clinicalâstage biopharmaceutical c...
Gemphire Therapeutics Inc. (NASDAQ:GEMP) is a c...
Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy ...
Atara Biotherapeutics is a leading off-the-shel...
TCR² is an innovative immunotherapy company developing the next generation of T c...
TCR² is an innovative immunotherapy company de...
Morphic Therapeutic is leading the development of a new generation of oral integri...
Morphic Therapeutic is leading the development ...
Join the National Investor Network and get the latest information with your interests in mind.